Panelists in this video:
+ Dr Subhrangshu Sengupta, VP – R&D – Formulation, IPCA Laboratories
+ Dr Pirthipal Singh, VP and Head R&D, Tirupati Group
+ Dr Sandhya Shenoy, AVP R&D, IPCA Laboratories
+ Dr Ravikumar N, EVP, MSN Laboratories
+ Dr Mayur Patel, Head-Formulation Development, APNAR Pharma
Moderator: Mr Manikandan Ramalingam, Sr VP-R&D, Granules India Limited
Key Highlights:
1) Dr Sandhya Shenoy, AVP R&D, IPCA Laboratories:
+ Overcoming permeability and stability challenges will be key for progress in oral biologics.
2) Dr Pirthipal Singh, VP and Head R&D, Tirupati Group:
+ 3D printing can provide the desired shape, colour and taste to pills, reduce pill burden, offer personalization, facilitate onsite manufacturing etc
3) Dr Mayur Patel, Head-Formulation Development, APNAR Pharma:
+ Digital pills can enable medicine adherence and prevent over dosage. But, fears of privacy breach, cost, lack of proof of concept are challenges to overcome
4) Manikandan Ramalingam, Sr VP-R&D, Granules India Limited:
+ Convenience, compliance and cost are the three Cs which are key for FR&D scientists. Patient centricity should be central to all innovations in FR&D
5) Dr Subhrangshu Sengupta, VP – R&D – Formulation, IPCA Laboratories:
+ Paediatric and geriatric polulations require medicines which are palatable, reduce pill burden and side effects and enables patient adherence.
6) Dr Ravikumar N, EVP, MSN Laboratories:
+ Novel excipients can help innovate and improve our old formulations and improve their efficiacy and effectiveness